- Home
- Publications
- Publication Search
- Publication Details
Title
Asciminib: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume 82, Issue 2, Pages 219-226
Publisher
Springer Science and Business Media LLC
Online
2022-01-18
DOI
10.1007/s40265-021-01662-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs
- (2021) Delphine Rea et al. BLOOD
- CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI)
- (2021) Michael J. Mauro et al. Clinical Lymphoma Myeloma & Leukemia
- Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment
- (2021) Matthias Hoch et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks
- (2021) Michael J. Mauro et al. BLOOD
- Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
- (2021) Alena Malyukova et al. Cell Death & Disease
- Pharmacokinetics of Asciminib When Taken With Imatinib or With Food
- (2021) Matthias Hoch et al. Clinical Pharmacology in Drug Development
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
- (2020) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Platelet function in patients with chronic myeloid leukemia treated with asciminib
- (2020) George Nesr et al. LEUKEMIA & LYMPHOMA
- Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects
- (2019) Phi Tran et al. XENOBIOTICA
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
- (2019) Christopher A. Eide et al. CANCER CELL
- Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
- (2019) Daniel J. DeAngelo et al. Clinical Lymphoma Myeloma & Leukemia
- Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
- (2019) Moshe Talpaz et al. Clinical Lymphoma Myeloma & Leukemia
- A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
- (2019) Marlise Luskin et al. BLOOD
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
- (2018) Laura N. Eadie et al. Oncotarget
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
- (2017) W Qiang et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Molecular biology of bcr-abl1-positive chronic myeloid leukemia
- (2008) A. Quintas-Cardama et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started